[ Price : $8.95]
X4 Pharmaceuticals files an NDA for a once-daily, oral mavorixafor to treat individuals aged 12 and older with WHIM (warts, hypoga...[ Price : $8.95]
Roche says recent data from its Phase 3 ALINA study evaluating Alecensa (alectinib) compared with platinum-based chemotherapy met ...[ Price : $8.95]
FDA posts a final guidance entitled Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium avium Complex (MAC): De...[ Price : $8.95]
FDA posts a draft guidance entitled Post-Warning Letter Meetings Under GDUFA that provides information on implementing the new pro...[ Price : $8.95]
Federal Register notice: FDA makes available a guidance to describe that enforcement policies will be extended for an additional y...[ Price : $8.95]
FDA clears a 23andMe 510(k) to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report by allowing it to re...[ Price : $8.95]
FDA says Universal Meditech has recalled all test products manufactured between 3/2021 and 11/2022 because the company is ceasing ...[ Price : $8.95]
Korea-based Hugel resubmits its BLA for its botulinum toxin Letybo (letibotulinumtoxinA), indicated for treating glabellar (frown)...